Artax Biopharma
Cambridge, United States · Biotechnology · 13 employees
Artax Biopharma is a development-stage biopharmaceutical company dedicated to the development of new therapies for autoimmune and inflammatory diseases. Artax Biopharma is developing the next generation of drugs targeting the interaction between TCR and Nck, which is responsible for T-cell activation. Specific control over T-cells through TCR, provides the compounds with the potential to become fi
Funding history
- Venture - Series Unknown — $19.0M — May 2026
- Venture - Series Unknown — $11.0M — Jul 2025
- Venture - Series Unknown — $11.0M — Aug 2024
- Venture - Series Unknown — $25.8M — May 2022
- Funding Round — Undisclosed — May 2022
Recent signals
- May 05, 2026: Raised $19.0M in Venture - Series Unknown
- Jul 29, 2025: Raised $11.0M in Venture - Series Unknown
- Aug 09, 2024: Raised $11.0M in Venture - Series Unknown
- Jan 04, 2024: Artax Announces Executive Team Changes, Expansion as Company Heads into Pivotal 2024 Year
- May 18, 2022: Raised $25.8M in Venture - Series Unknown
- May 11, 2022: Raised funding in Funding Round
- Jan 03, 2022: Raised $12.7M in Venture - Series Unknown
- Feb 26, 2021: Raised $2.2M in Seed
See plans & pricing → Track Artax Biopharma’s funding, hiring, and signals — with verified contacts — on Fundz.